Howard S. Hochster, MD

Articles by Howard S. Hochster, MD

Chemotherapy Drug Shortages: It’s Soluble

November 9th 2023

Howard S. Hochster, MD, reviews the potential solutions for the current chemotherapy drug shortages, and how this can be avoided in the future.

Drug Price Negotiations: One Long-Overdue “Small Step” for the American Health Care Consumer

ByHoward S. Hochster, MD

September 14th 2023

Co-editor-in-chief, Howard S. Hochster, MD, reviews the ongoing drug price negotiations and the effect it will have in the health care space.

PROSPECT: A Study Whose Time Is Past

ByHoward S. Hochster, MD

July 28th 2023

Co-editor-in-Chief Howard S. Hochster, MD, writes about the past and present of the phase 2/3 PROSPECT trial.

The Painful Problem of Biosimilars in the Clinic

ByHoward S. Hochster, MD

May 11th 2023

Co-editor-in-Chief Howard S. Hochster, MD, discusses persistent obstacles to the effective use of biosimilars in clinical practice.

Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma

ByDaniel V. T. Catenacci, MD,Yoon-Koo Kang, MD, PhD,Hope E. Uronis, MD, MHS,Keun-Wook Lee, MD, PhD,Matthew C. H. Ng, MD,Peter C. Enzinger, MD,Se Hoon Park, MD, PhD,Philip J. Gold, MD,Jill Lacy, MD,Howard S. Hochster, MD,Sang Cheul Oh, MD, PhD,Yeul Hong Kim, MD, PhD,Kristen A. Marrone, MD,Ronan J. Kelly, MD,Rosalyn A. Juergens, MD,Jong Gwang Kim, MD, PhD,Thierry Alcindor, MD, MSc,Sun Jin Sym, MD, PhD,Eun-Kee Song, MD, PhD,Cheng Ean Chee, MD,Yee Chao, MD, PhD,Sunnie Kim, MD,Do-Youn Oh, MD, PhD,Jennifer Yen, PhD,Justin I. Odegaard, MD, PhD,Errin Lagow, PhD,Daner Li, MS,Jichao Sun, PhD,Patrick Kaminker, PhD,Paul A. Moore, PhD,Minori Koshiji Rosales, MD, PhD,Haeseong Park, MD, MPH

April 27th 2023

Daniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.

Updated Data and Groundbreaking Research Lead to an Exciting 2023 ASCO GI

ByHoward S. Hochster, MD

March 29th 2023

Co-editor-in-Chief Howard S. Hochster, MD, highlights the most exciting developments from the 2023 Gastrointestinal Cancer Symposium hosted by the American Society of Clinical Oncology (ASCO).

Increasing Breast Cancer Diagnosis in Rural Areas and the Evolving Access to Health Care

ByHoward S. Hochster, MD

January 26th 2023

Co-editor-in-Chief Howard S. Hochster, MD, discusses disparities in access to health care between urban and rural patients with breast cancer, and how they might be addressed.

2022: The Oncology Year in Review

ByHoward S. Hochster, MD

December 23rd 2022

Co-editor-in-Chief Howard S. Hochster, MD, reviews the major clinical and scientific developments of 2022 in the oncology space.

You Can Help Set New Paradigms Involving ctDNA

ByHoward S. Hochster, MD

October 11th 2022

Co-editor-in-Chief Howard S. Hochster, MD, highlights exciting clinical trials that may set future standards for adjuvant therapy selection in colon cancer.

Is Drug Price Negotiation a Concept Whose Time Has Come?

ByHoward S. Hochster, MD

September 13th 2022

Howard S. Hochster, MD, considers drug price negotiation in this month's Letter to the Readers.

A Pilot Study of Omalizumab to Treat Oxaliplatin-Induced Hypersensitivity Reaction

ByStacey Stein, MD,Kirsten Dooley, BS, APRN,Nataliya V. Uboha, MD, PhD,Howard S. Hochster, MD

July 18th 2022

Stacy Stein, MD, and co-investigators, research omalizumab to treat oxaliplatin hypersensitivity reactions for patients with gastrointestinal cancers.

Platinum Hypersensitivity Reaction (HSR): An Ongoing Problem in Cancer Treatment

ByHoward S. Hochster, MD

July 12th 2022

In this month's Letter to the Readers, ONCOLOGY co-editor-in-chief Howard S. Hochster, MD, discusses oxaliplatin hypersensitivity reaction in gastrointestinal cancer.

CRISPR Patent Battle: Beautiful Science, Poor Public Policy

ByHoward S. Hochster, MD

May 10th 2022

In this month's Letter to the Readers, ONCOLOGy co-editor-in-chief Howard Hochster, MD, reviews the implications of legal disputes surrounding patents for CRISPR technology.

The Emerging Value of ctDNA in Colon Cancer Adjuvant Therapy Decisions

ByHoward S. Hochster, MD

March 10th 2022

In this month’s Letter to the Readers, ONCOLOGY co-editor-in-chief Howard S. Hochster, MD, reviews results of the CIRCULATE-Japan clinical trial that were presented at the 2022 Gastrointestinal Cancers Symposium.

The Unhappy Intersection of Cancer and COVID-19

ByHoward S. Hochster, MD

August 9th 2021

ONCOLOGY® co-editor-in-chief Howard S. Hochster, MD, reviews research on delays in oncology care as a result of the COVID-19 pandemic.

Oncology Peer Review On-The-Go: BPCIA, 4-Letter Suffix Rule, & the Challenges of Prescribing Biosimilars

ByMatthew Fowler,Howard S. Hochster, MD,Michael Kane, RPh, BCOP

July 6th 2021

CancerNetwork®’s podcast hosted 2 experts to discuss the current state of biosimilar prescriptions and the need for change to improve the system overall.

Next-Generation Sequencing for Advanced Pancreatic Cancer: A Technology Whose Time Has NOT Come

ByHoward S. Hochster, MD

May 15th 2021

In his "Letter to the Readers", co-editor-in-chief of the journal ONCOLOGY Howard S. Hochster, MD, reviews the utility of next-generation sequencing in pancreatic ductal adenocarcinoma.

Messenger RNA: A Technology of the Moment

ByHoward S. Hochster, MD

April 16th 2021

In his "Letter to the Readers", co-editor-in-chief of the journal ONCOLOGY Howard S. Hochster, MD, reviews the development of mRNA technology, especially as it applies to vaccines against COVID-19.

WANTED: An “All-Out” National Vaccination Program

ByHoward S. Hochster, MD,Julie M. Vose, MD, MBA

February 2nd 2021

Unprecedented efforts from researchers and pharmaceutical engineers have brought about safe, effective vaccines, in record development times; now the focus must be on a federally coordinated program to administer those injections in the most efficient manner possible.